Vaccines, Virus-Like Particle
"Vaccines, Virus-Like Particle" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines using supra-molecular structures composed of multiple copies of recombinantly expressed viral structural proteins. They are often antigentically indistinguishable from the virus from which they were derived.
| Descriptor ID |
D058425
|
| MeSH Number(s) |
D12.776.828.868.955 D20.215.894.865.955 D23.050.865.955
|
| Concept/Terms |
Vaccines, Virus-Like Particle- Vaccines, Virus-Like Particle
- Particle Vaccines, Virus-Like
- Vaccines, Virus Like Particle
- Virus-Like Particle Vaccines
- Virus Like Particle Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, Virus-Like Particle".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Virus-Like Particle".
This graph shows the total number of publications written about "Vaccines, Virus-Like Particle" by people in this website by year, and whether "Vaccines, Virus-Like Particle" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 4 | 0 | 4 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vaccines, Virus-Like Particle" by people in Profiles.
-
A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. J Infect Dis. 2024 May 15; 229(5):1402-1407.
-
A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans. Sci Transl Med. 2023 05 17; 15(696):eade8273.
-
COVID-19 vaccine decisions: considering the choices and opportunities. Microbes Infect. 2021 May-Jun; 23(4-5):104811.
-
E. coli production process yields stable dengue 1 virus-sized particles (VSPs). Vaccine. 2020 04 09; 38(17):3305-3312.
-
Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants. J Infect Dis. 2019 10 22; 220(11):1802-1815.
-
Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination. J Infect Dis. 2019 07 19; 220(4):603-614.
-
An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults. J Infect Dis. 2019 01 09; 219(3):410-414.
-
A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017 06 27; 35(30):3749-3759.
-
B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine. Clin Vaccine Immunol. 2017 May; 24(5).
-
Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. Vaccine. 2016 11 21; 34(48):5886-5894.